These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37317744)
1. Outcome of COVID-19 in patients with autoimmune bullous diseases. De D; Ashraf R; Mehta H; Handa S; Mahajan R Indian J Dermatol Venereol Leprol; 2023; 89(6):862-866. PubMed ID: 37317744 [TBL] [Abstract][Full Text] [Related]
2. Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study. Moghadam FS; Kianfar N; Dasdar S; Samii R; Farimani Z; Azar PM; Balighi K; Abedini R; Soori T; Farid AS; Mahmoudi H; Daneshpazhooh M Dermatol Ther; 2022 Sep; 35(9):e15672. PubMed ID: 35768959 [TBL] [Abstract][Full Text] [Related]
3. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. Ohata C; Ishii N; Koga H; Fukuda S; Tateishi C; Tsuruta D; Furumura M; Hashimoto T J Am Acad Dermatol; 2015 Jul; 73(1):50-5. PubMed ID: 25896671 [TBL] [Abstract][Full Text] [Related]
4. Severe acute respiratory syndrome coronavirus 2 infection in patients with autoimmune bullous diseases in China. Zhang JL; Wang SH; Cui SN; Zhang J; Li SZ; Li L; Zuo YG J Dermatol; 2023 Nov; 50(11):1433-1441. PubMed ID: 37501390 [TBL] [Abstract][Full Text] [Related]
5. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086 [TBL] [Abstract][Full Text] [Related]
6. Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine. Pira A; Sinagra JLM; Moro F; Mariotti F; Di Zenzo G Front Med (Lausanne); 2023; 10():1112823. PubMed ID: 36744126 [TBL] [Abstract][Full Text] [Related]
7. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610 [TBL] [Abstract][Full Text] [Related]
8. Risk factors of rituximab-induced thrombocytopenia in patients with autoimmune bullous diseases. Lee SG; Kim SC; Kim JH J Dermatol; 2024 Apr; 51(4):597-601. PubMed ID: 37830427 [TBL] [Abstract][Full Text] [Related]
9. Pediatric autoimmune blistering disorders - a five-year demographic profile and therapy experience. Mahajan R; Handa S; Kumar S; Chatterji D; Saikia UN; De D Int J Dermatol; 2022 Dec; 61(12):1511-1518. PubMed ID: 35894223 [TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of autoimmune bullous diseases in Middle Franconia. Sollfrank L; Schönfelder V; Sticherling M Front Immunol; 2023; 14():1256617. PubMed ID: 37881435 [TBL] [Abstract][Full Text] [Related]
11. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444 [TBL] [Abstract][Full Text] [Related]
12. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481 [TBL] [Abstract][Full Text] [Related]
14. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy. Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538 [TBL] [Abstract][Full Text] [Related]
15. Spectrum of autoimmune bullous diseases among children in Kuwait. Nanda A; Lazarevic V; Rajy JM; Almasry IM; AlSabah H; AlLafi A Pediatr Dermatol; 2021 Jan; 38(1):50-57. PubMed ID: 33043506 [TBL] [Abstract][Full Text] [Related]
16. Retrospective Study on Autoimmune Blistering Disease in Paediatric Patients. Kong YL; Lim YL; Chandran NS Pediatr Dermatol; 2015; 32(6):845-52. PubMed ID: 26391853 [TBL] [Abstract][Full Text] [Related]
17. New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review. Wu PC; Huang IH; Wang CY; Chi CC Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793716 [TBL] [Abstract][Full Text] [Related]
18. Oral health related qualıty of lıfe and dısease severıty ın autoımmune bullous dıseases. Bilgic A; Aydin F; Sumer P; Keskiner I; Koc S; Bozkurt S; Mumcu G; Alpsoy E; Uzun S; Akman-Karakas A Niger J Clin Pract; 2020 Feb; 23(2):159-164. PubMed ID: 32031089 [TBL] [Abstract][Full Text] [Related]
19. [Oesophageal bullous detachment with massive haemorrhage revealing acquired haemophilia A in autoimmune bullous dermatosis]. Bonigen J; Laly P; Tran-Minh ML; Hau E; Guibal F; Bagot M; Petit A Ann Dermatol Venereol; 2020 Mar; 147(3):217-220. PubMed ID: 31831217 [TBL] [Abstract][Full Text] [Related]
20. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. Behkar A; Garmaroudi G; Nasimi M; Yousefi S; Khosravi H; Kianfar N; Murrell DF; Daneshpazhooh M Int J Womens Dermatol; 2022 Mar; 8(1):e004. PubMed ID: 35620025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]